...
首页> 外文期刊>Radiation oncology >Adding concurrent chemotherapy to postoperative radiotherapy improves locoregional control but Not overall survival in patients with salivary gland adenoid cystic carcinoma—a propensity score matched study
【24h】

Adding concurrent chemotherapy to postoperative radiotherapy improves locoregional control but Not overall survival in patients with salivary gland adenoid cystic carcinoma—a propensity score matched study

机译:术后放疗中同时进行化疗可改善局部区域控制,但唾液腺腺样囊性癌患者的总生存率未得到改善-倾向得分匹配研究

获取原文

摘要

Purpose To compare the long-term outcomes in patients with salivary gland adenoid cystic carcinoma (SGACC) treated with post-operative chemoradiotherapy (POCRT) versus post-operative radiotherapy (PORT). Methods We retrospectively reviewed the records of 91 SGACC patients treated with surgery followed by PORT ( n =?58) or POCRT ( n =?33) between 2000 and 2013. Treatment outcomes between groups were compared using propensity score matching (1:1 nearest neighbor). Results The median radiation dose was 66?Gy, and patients were followed up for a median of 71?months. Cisplatin-based concurrent regimens were the most commonly used chemotherapy schedules. In the entire study cohort, patients undergoing POCRT showed a trend toward higher locoregional control (LRC) rates than those treated with PORT alone at both 5 and 8?years (97 and 97?% versus 84 and 79?%, respectively; P =?.066). Distant metastases were the most common form of treatment failure and occurred in 31 (34?%) patients (PORT, n =?17; POCRT, n =?14). After propensity score matching (33 pairs), patients receiving POCRT had 5- and 8?year LRC rates of 97 and 97?%, respectively, compared with 79 and 67?% for patients treated with PORT alone ( P =?.017). The two groups did not differ significantly in terms of distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS). However, a significantly better opioid-requiring pain-free survival (ORPFS) was achieved in POCRT group ( P =?.038). Subgroup analyses revealed that patients with stage III???IV disease ( P =?.040 and .017), positive surgical margins ( P =?.011 and .050), or perineural invasion ( P =?.013 and .035) had significantly higher 5- and 8?year LRC and ORPFS when treated with POCRT, respectively. Conclusions In SGACC patients, adding concurrent chemotherapy to PORT may increase LRC and ORPFS rates, particularly in presence of stage III???IV disease, positive surgical margins, or perineural invasion. However, no significant differences in DMFS, DFS, and OS were observed.
机译:目的比较术后放化疗(POCRT)和术后放疗(PORT)治疗的涎腺腺样囊性癌(SGACC)患者的远期结局。方法回顾性分析2000年至2013年间91例接受手术治疗的SGACC患者,并进行PORT(n =?58)或POCRT(n =?33)治疗的记录。采用倾向评分匹配(1:1最近)比较两组间的治疗结果。邻居)。结果中位放射剂量为66?Gy,患者随访中位时间为71?个月。基于顺铂的并发方案是最常用的化疗方案。在整个研究队列中,接受POCRT的患者在5年和8年时均显示局部区域控制(LRC)率高于单独PORT治疗的患者(分别为97%和97%,84%和79%; P = ?066)。远处转移是治疗失败的最常见形式,发生于31名(34%)患者(PORT,n = 17; POCRT,n = 14)。倾向评分匹配后(33对),接受POCRT的患者的5年和8年LRC率分别为97%和97%,而仅接受PORT治疗的患者的79年和67 %%(P = ?. 017) 。两组在远处无转移生存期(DMFS),无病生存期(DFS)和总体生存期(OS)方面无显着差异。但是,在POCRT组中,阿片类药物的无痛生存期(ORPFS)显着提高(P = ?. 038)。亚组分析显示,患有III期Ⅳ期疾病(P = 0.014和0.017),手术切缘阳性(P = 0.011和0.050)或神经周围浸润(P = 0.013和0.035)的患者)接受POCRT治疗的5年和8年LRC和ORPFS分别显着升高。结论在SGACC患者中,在PORT上同时进行化疗可能会增加LRC和ORPFS的发生率,特别是在存在IV期IV期疾病,手术切缘阳性或神经周浸润的情况下。但是,未观察到DMFS,DFS和OS的显着差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号